Why Akorn Shares Were Halved

Akorn shares were crushed early on Monday after a Delaware judge ruled that German health care group Fresenius could walk away from its $4.75 billion merger deal.

Published October 1, 2018, 10:25am ET · 1 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A close-up digital display of a stock market candlestick chart. The left side features prominent glowing green candlesticks and lines, indicating an upward trend. Towards the center and right, the chart transitions into glowing red candlesticks and lines, showing a significant downward trend. The background is a dark, pixelated grid with blurred green and red digital information.
A digital stock chart displays a mix of green uptrends and red downtrends, reflecting the fluctuating nature of financial markets and individual stock performance. © Thinkstock

Akorn Inc. (NASDAQ: AKRX) shares were crushed early Monday after a Delaware judge ruled that German health care group Fresenius could walk away from its $4.75 billion deal for Akorn and rejected Akorn’s claim that the merger agreement had been breached.

Note that shares were halted as trading began on Wall Street.

Delaware’s Vice Chancellor Travis Laster noted that Fresenius validly terminated the merger agreement and he found Akorn’s representations regarding its compliance with regulatory requirements were “not true and correct.”

The deal originated late in April 2017, when Fresenius offered to buy Akorn for $34 per share, in an all cash transaction.

[nativounit]

The company issued a statement in regards to the ruling:

We are disappointed by the ruling by the Delaware Chancery Court determining not to force Fresenius to close and we continue to believe Fresenius’ attempt to terminate the transaction is in breach of our binding merger agreement. We intend to appeal, in an effort to vigorously enforce our rights and continue to protect the interests of our Company and our shareholders.

Excluding Monday’s move, Akorn had underperformed the broad markets, with the stock down about 60% in the past 52 weeks.

Shares of Akorn were last seen trading down 55% at $5.77, with a consensus analyst price target of $27.25 and a 52-week range of $5.66 to $33.63.

[recirclink id=496101]

[wallst_email_signup]

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

All articles →